



CHRISTOPHER A. SHAW

NEURAL
DYNAMICS
— OF —
NEUROLOGICAL
DISEASE

WILEY Blackwell

Neural Dynamics of Neurological Disease

Christopher A. Shaw

Department of Ophthalmology and Visual Sciences,
University of British Columbia,
Canada

WILEY Blackwell

Copyright © 2017 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data

Names: Shaw, Christopher A. (Christopher Ariel), author.

Title: Neural dynamics of neurological disease / Christopher A. Shaw.

Description: Hoboken, New Jersey : John Wiley & Sons, Inc., [2017] | Includes bibliographical references and index.

Identifiers: LCCN 2016051232 (print) | LCCN 2016051536 (ebook) | ISBN 9781118634578 (cloth) | ISBN 9781118634479 (pdf) | ISBN 9781118634738 (epub)

Subjects: | MESH: Central Nervous System Diseases | Disease Progression | Aging—physiology

Classification: LCC RC346 (print) | LCC RC346 (ebook) | NLM WL 301 | DDC 616.8—dc23

LC record available at <https://lccn.loc.gov/2016051232>

Cover credit: © Karen Santos 2015

Cover design: Wiley

Set in 10/12pt Warnock by SPi Global, Chennai, India

Printed and bound in Malaysia by Vivar Printing Sdn Bhd

10 9 8 7 6 5 4 3 2 1

Preface

"Babylon in all its desolation is a sight not so awful as that of the human mind in ruins."

Scrope Berdmore Davies¹

"I can face death, but I cannot face watching myself disappear from within...I don't know who I am anymore."

Claude Jutra²

Each annual meeting of the Society for Neuroscience (SfN) is, for me, once more a reminder just how reductionist the field of neuroscience has been, continues to be, and apparently is destined to remain.

Anyone who has gone to this conference, or any similar type of large meeting, cannot help but be overwhelmed by the sheer quantity of the information on display. During the three and a half days of the main SfN meeting, some 30 000 participants will present over 15 000 posters along with almost 13 000 talks of various lengths. These numbers were the projected figures for the 2014 conference in Washington, DC, but other SfN conferences of the recent past will have been much the same in size. Future conferences will likely be even larger.

Most of the talks at the meeting occur in the so-called "mini"- and "nano"-symposia which feature 15-minute-long presentations, each usually containing a small body of data and its preliminary interpretation. However, the poster sessions really show the true dimensions of the conference: seven 4-hour-long sessions, each filling an area the size of several football fields.

Each poster, or mini-talk, contains a snippet of information – almost all of it, as noted, preliminary – a lot of which will turn out to be conceptually flawed in design or experimentally incorrect. Much of the time, as the lack of later publications bears out, the work is simply not reproducible. This outcome is in accord with studies by various scholars who have noted a lack of reproducibility in experimental data of all kinds, perhaps particularly often in the biomedical sciences.

Multiply these numbers by the additional numbers of people and presentations at conferences in neurology or more specialist neurological diseases, multiply again by the number of years these conferences have all been going on, and one likely gets billions of words and millions of tons of paper in a virtual tidal wave of information, which, combined with endless time spent by a great variety of otherwise quite talented scientists,

actually produces what, at the end of the day, amounts to relatively little useful information about neurological diseases. Further, very little of this information is actually sorted, compiled, or cross-checked internally or externally with the previous decades of results from all of the similar meetings.

What then are the outcomes for neurological disease remediation? First, the field still does not understand the etiology of most neurological diseases, and, as a consequence, it has only a very limited means of translating what it thinks it knows into treatments that actually halt the progression of – never mind “cure” – these diseases.

The problem here is therefore obviously not one of quantity, or even in many cases of quality. Rather, the problem is that the field still cannot answer some really fundamental questions about the diseases in question and therefore cannot come up with treatments that make a lot of sense mechanistically or, at the very least, do what they are intended to do. Maybe what this really means is that the field of neurological disease research is not asking the right questions, or that it does not know how to interpret the answers.

For me, the question is not how to (over) simplify the nervous system and its diseases, but rather how to understand them in their entirety. Admittedly, the task of understanding the former has proven quite difficult. The second goal clearly depends on accomplishing the first.

As other authors have pointed out in different contexts, attempts to “atomize” a subject of study into ever smaller bits without any context to their inter-relationships can be enormously detrimental (see, for example, Gould and Lewontin, 1979). Further, should the field really expect that a system as complex as the nervous system will break down in a simple way, or should it expect that its pieces will, in some measure, reflect its overall innate complexity? Almost for sure, it is the latter. At least, this is the perspective I will take in the pages that follow. I should acknowledge here that my bias against overusing reductionist approaches when considering neurological disease origins in as complex a system as the human central nervous system (CNS) is very much the polar opposite to the tack taken by Dr. Christof Koch, one of the foremost theorists on human consciousness (see Koch, 2012). The latter subject is surely as complex as the breakdown of the CNS in neurological diseases, but there may be some common ground (see Chapter 14).

As will be discussed in this book, the origin, function, and diseases of the nervous system are, by their very nature, complex, and are highly interconnected amongst the various types of cells and regions affected. The concept of biosemiosis, or biological signaling, is in this context highly relevant, and it will be highlighted in much of the discussion that follows. Moreover, the diseases upon which this book will focus are “progressive,” meaning that they continue to get worse in terms of nervous system pathology and functioning over time. They are also age-related and somewhat sex-dependent, are complicated by the added complexities of genetic variations, individual microbiomes, and a host of other likely contributing factors.

How all of these aspects combine to produce any neurological disease is actually something that neurological disease research has not really begun to understand. If the nervous system is constructed as a complex system both developmentally and functionally, which it decidedly is, then it is surely so when it malfunctions. In brief, those of us in what can broadly be described as the neurological disease “field,” a term that will be used throughout the book, are in rather dire need of a conceptual frame shift.

Many scientists are hard at work to accomplish such a shift, but they are swimming against a powerful tide of overwhelming amounts of data, which, as noted earlier, are

often incorrect. How, then, is one to sort the wheat from the chaff, the valid from the invalid?

This book is intended to help the process along. Inevitably, in so doing, it will annoy some of my neuroscience colleagues as it may seem to imply that all their myriad experiments – often with amazingly spectacular methodologies – are not going to get the field to any answers without reframing the questions. Techniques are, after all, merely the equivalent of tactics in a military setting, simply, in this case, the means to accomplish the larger strategic goal of understanding these diseases. The strategic goal is aimed at an end state of prevention (or of effective treatment, as the second-best option).

Understanding this end state is actually critical to our collective wellbeing, because these various diseases are threatening to overwhelm the medical systems of the developed nations. (As for the developing countries, their medical systems are in many cases in poor enough shape as is, and hardly need the added burden of increased neurological diseases.)

My hope is that *Neural Dynamics of Neurological Disease* will spark debate. Time will tell if this hope has been realized. While desirable, indeed essential, from my perspective, such an outcome is decidedly a long shot. Scientific journals and meetings such as the SfN have become major industries, and are often mired in dogma, with an apparently dominant philosophy that “more equates to better.”

It is clear from the work of Prof. John Ioannidis and others that more is not necessarily better if the data are incorrect or interpreted incorrectly and/or are not verified by replication, or at least convergent forms of information. Thus, of the approximately 28 000 talks and poster presentations at SfN, some two-thirds (or more) will be incorrect, and virtually none will be replicated. This is a vastly larger problem than most of those in the field realize, and I will touch upon it further in Chapter 8.

It is reasonable to assume that much of what follows in this book will be controversial, not so much because the data are contested (although in many cases they are) but because the way I have chosen to put them together in particular categories leads to certain conclusions. Other authors, ordering the subjects in different ways, might reach very different outcomes. In this sense, the process of writing a book is a lot like museum curatorship in that what one chooses to put on display versus what one leaves in the basement will provide very different narratives. When writing about neurological diseases, how one collates and arranges the key subjects and lesser items shapes the presentation, and thus the conclusions. And, needless to say, all authors have their own assumptions, prejudices for or against certain hypotheses and data, and ways of viewing any particular field of study.

Given this, it seems only fair at the outset for me to state my own assumptions. These are listed in a sequence from what I hope will be the least controversial, “motherhood” sorts of assertions to those that perhaps deviate to a lesser or greater extent from mainstream concepts of the nervous system in disease. Each will be bolstered by the relevant literature in the appropriate places in the book’s chapters.

One point to be addressed first, however, is the following: the terms “disease” and “disorder” tend to be used synonymously when speaking of those conditions that afflict the human nervous system. This consideration applies particularly to those diseases that are the main focus of this book, namely Parkinson’s disease, amyotrophic lateral sclerosis (ALS) (colloquially called Lou Gerhig’s disease, although it might just as well have been termed Charcot’s disease, as it sometimes has been), and Alzheimer’s disease. Is it correct to term these conditions “diseases”? The difference between the two words can be

subtle. “Disease” is normally used in the sense of sickness or illness. These neurological conditions fit this definition, and hence their names are appropriate. In addition, there is some evidence – not particularly strong, but evidence nevertheless – that they actually arise as part of an infectious process. Hence, calling them “diseases” is even more correct. In regard to the word “disorder,” various dictionaries define it to mean “an illness that disrupts normal physical or mental functions.” These conditions definitely do both, so it is equally correct to refer to them as “disorders.” Therefore, with apologies to the purists amongst the readers, the terms “neurological disease” and “neurological disorder” will be used interchangeably in the chapters that follow. When speaking of specific conditions (e.g., Alzheimer’s disease), the word “disease” will always be used.

With that out of the way, I want to introduce the central theses to be addressed, not necessarily in the following order:

- 1) The human CNS is complex. It contains something on the order of 86 billion neurons, organized into multiple subsystems, surrounded by 85 billion supporting glial cells. Neurons are totally dependent on these support cells for their normal functions. Each neuron connects to multiple other neurons for an estimated 94 trillion synaptic connections. There should be nothing particularly controversial about anything in this paragraph for anyone in neuroscience/neurological disease research.
- 2) The complexity of the nervous system arises due to the interplay between genetic programs and environmental influences. This complexity includes the interactions that lead to neurodegeneration. Gene defects in the germ cell line and in the early developing CNS are likely to be fatal or result in profoundly disturbed neuronal functions. Environmental impacts on the CNS depend crucially on the stage of development: prenatal ones are likely to be of greater impact than those occurring in postnatal life, while early postnatal ones will be more impactful than those later in life. The concept of the “fetal basis of adult disease” used in other fields of study likely applies to neurological disease just as strongly (or even more so) to those disorders with which it is more conventionally associated. Environmental impacts also crucially depend on the number of CNS levels impacted (e.g., from genome to the whole CNS).
- 3) It is almost certain that gene defects/mutations alone will not explain most types of age-related neurological disease. Nor, for that matter, will obvious environmental stressors/toxins be found to be solely responsible in most cases. Hence, gene–toxin interactions are the likely source of most such diseases, acted upon by a number of other variables across the lifespan.
- 4) Neuronal compensation for genetic or environmental insults to the CNS will be limited by the type of insult and the stage(s) at which they occurs. Early gene defects, if not rapidly fatal, may be compensated for by redundancy of function of other genes. Environmental impacts, if they do not cross too many levels of organization, may allow for neuronal compensation by unaffected cells or regions. “Neuronal plasticity” is not a simple process, nor one strictly limited to the stage of neuronal development.
- 5) For all of these reasons, neurological diseases that are age-related (e.g., Parkinson’s disease, ALS, Alzheimer’s disease, and others) are going to be complex as well. The same applies to neuronal disorders at the other end of the age spectrum (e.g., autism spectrum disorder (ASD)).

- 6) At least for Parkinson's disease, ALS, Alzheimer's disease, there is only one, possibly two, real neurological clusters with a sufficient number of afflicted patients to allow effective epidemiology. The first cluster is ALS–parkinsonism dementia complex (ALS-PDC) of the Western Pacific. This includes the islands of Guam and Rota (where it was first described), Irian Jaya, and perhaps the Kii Peninsula of Japan (whether the CNS disorders in Kii are related to the others is an area of some controversy). The second possible cluster is the form of parkinsonism associated with consumption of the soursop fruit on the French Caribbean island of Guadeloupe.
- 7) The gene–toxin interactions leading to neurological diseases are not CNS-specific, but impact other organ systems as well. They may not be the cause of death or nervous system dysfunction, but ignoring these other organ impacts misses a number of crucial clues to disease etiology.
- 8) Still other organ systems are likely significantly involved in neurological diseases. A good example is the immune system in which autoimmune reactions may be a primary player in the onset and progression of some neurological diseases. The immune system also plays important roles in normal neuronal development.
- 9) Because of the complexity and interconnectedness of the CNS, damage at any level must necessarily cascade to other levels (e.g., cell to circuit, circuit to a particular region, etc.). So-called “cascading failures” will, at some point, trigger a total system collapse. Thus, after such a critical stage is reached, no effective therapy will be possible. For this reason, therapies designed to target late stages of disease, namely most at the “clinical” diagnosis stage, will inevitably fail and may simply exacerbate rather than relieve underlying pathological processes. The concepts from biosemiosis of the “true narrative representation” (TNR) apply here.
- 10) Any models of neurological diseases, no matter what kind of model or for which disease, are at best a limited means of understanding the complexity of the particular disease. They are even less effective in developing therapeutic approaches to early or late disease states.
- 11) Many of the data in the literature in any of the subfields of neurological disease research are likely to be wrong and thus highly misleading. Each subfield needs a thorough review to cull such incorrect material. This is not likely to happen.
- 12) Each of the sporadic/gene-susceptibility age-dependent neurological diseases represents not one entity but a spectrum of related disease states. Each case is therefore individual. Against such individual (and thus, unique) presentations, there can never be a generalized treatment. This applies particularly if treatment options are begun post-diagnosis. Effective treatments for neurological diseases, if they occur at all, can arise only from prophylaxis or the next-best option of extremely early-phase detection followed by strategic, targeted therapy. The only way to get to this stage is for governments and other entities to commit significant funds to providing a new perspective on such diseases. Essentially, this is a policy discussion, in which social priorities need to be carefully examined. Policy considerations are not the traditional role of scientists, but without the input of those doing the research, a policy re-evaluation will almost certainly not happen. Whether it does or does not is a choice. Needless to say, choices have consequences.

These last comments are really the focus of this book, and were fleshed out from some very preliminary thoughts as I walked the Camino Frances of the Camino de Santiago. For those who do not know it, the Camino actually describes a number of routes, mostly

in Spain and France, which all end up in the Galician city of Santiago de Compostella. Even on a single route, although the conventional end point remains the same, the geography can vary from year to year, as a result of human activity and weather. How one actually walks the Camino varies with season, personal fitness, past or acquired injuries, frame of mind, companions, and so on. Not everyone finishes. For those who do complete the Camino, no two journeys are the same. Thus, one often hears the expression, “walking one’s own Camino.”

All of this leads to the point hinted at earlier: no two neurological disease manifestations, even in ostensibly the same disease, are actually the same, except perhaps at disease end state. Everyone walks their own Camino of neurological health. This metaphor, I think, has significant implications for neurological disease detection and treatment.

Four final points – caveats, really – need to be acknowledged, all of which will be discernible to readers in due course. First, just as neurological diseases are not linear in how they develop, progress, or complete, this book is not linear either. While there is a trajectory that leads from the first pages to the final conclusions, the book could not be written as if it were a simple story. Rather, it is recursive in fact and concept, with various themes being introduced and then reconsidered pages later as new information is added. Some readers may find that this makes parts of the book redundant. I hope, however, that such readers will see that any one such theme is expanded by the stage of the book and the discussions that have occurred since it was last raised.

Second, in some sections I describe the work of my laboratory and colleagues in more detail than I do the work of others. The reason is simple: I know my own work best – the valid parts as well as the invalid. I hope I have not done such self-selection too blatantly, or too often.

Third, in areas that are likely to prove particularly controversial, I err on the side of providing too many, rather than too few, primary literature references. This point ties in with the fourth caveat: The book is written mostly for my fellow neuroscientists and for those in the neurological disease world. This focus inevitably leads to some pretty dense – and reference-filled – expositions, which may be daunting for any nonspecialist scientists or the lay public. A glossary is provided at the end, which I hope will help.

That about sums it up.

Needless to say, in all of the following material, any errors in citation, content, or interpretation are purely my own.

*Christopher A. Shaw
Victoria, BC, Canada*

Endnotes

- 1 Scope Berdmore Davies (1782–1852) was a dandy and friend of Lord Byron.
- 2 Claude Jutra (1930–1986) was a Quebecois director, screenwriter, film editor, cinematographer, and actor. After being diagnosed with Alzheimer’s and living with the condition for a time, Jutra committed suicide. In recent years, his reputation has been stained by allegations of pedophilia.

Acknowledgments

This book owes much to a number of individuals, for a great variety of reasons. First, I thank Justin Jeffryes of John Wiley & Sons for suggesting the project and for tolerating my numerous requests for extensions. The various support persons at Wiley were a pleasure to work with throughout the entire process and I am most grateful for their efforts on behalf of the book. Next, thanks are due to Claire Dwoskin for her financial support to my laboratory and her boundless encouragement in all things. Other supporters were the Luther Allyn Dean Shourds estate, the Kaitlin Fox Foundation, and various more official granting agencies, including the National Institutes of Health and the US Department of Defense.

My laboratory mates provided endless enthusiasm and cogent conversation, acted as sounding boards, and offered much other help as the project emerged. In no particular order, these were: Dr. Alice Li, Sneha Sheth, Jess Morrice, and others listed more specifically in the following.

Janice Yoo and Jessie Holbeck were most helpful in tracking down references and summarizing blocks of data for various chapters. In regard to the data summaries, Janice in particular was an amazing source, and her summaries enabled various sections to be completed. Indeed, without Janice, the book would not have been finished in anything like a timely manner. As the final deadline loomed, Janice took over all of the formatting and reference checking. For all of these reasons, my gratitude to her is boundless. Katie Blank did a fantastic job with the figures and tolerated my endless revisions. I also owe her a special debt of gratitude. Michael Kuo did final formatting, reference checks, and a huge range of jobs associated with getting this book through the copy editing and galley proof stages. I owe him a huge debt of gratitude as well.

Pierre Zweigers designed some figures for the ALS portion of the book and provided much useful discussion and commentary on several early drafts of some chapters. Bob Quellos provided valuable information on aspects of architecture. Dr. Thomas Marler of the University of Guam was kind enough to take pictures of cycads for the book. Dr. John Steele of Guam was most generous in allowing me access to some figures from his work and from the historical record on ALS-PDC. Dr. Greg Cox of Jackson Laboratories and Prof. Steven Hyman of the Broad Institute kindly provided copies of their Power-Point presentations on ALS animal models and the coming crisis in neurological disease research funding, respectively. Prof. Roger Berkowitz of the Hannah Arendt Center for Politics and Humanities of Bard College was kind enough to find the Hannah Arendt quote I use in Chapter 16. Prof. John Oller, Dr. Lucija Tomljenovic, Micheal Vonn, and Darcy Fysh provided extremely valuable critiques on drafts of part, or all, of the book. I owe much to those in the laboratory of Prof. Romain Gherardi for their kindness and

guidance during my sabbatical in Paris. This includes not just Romain himself, but Profs. E.-J. Authier and Josette Cadusseau and various students and staff as well.

A posthumous thank you is due to my former PhD supervisor, Prof. Peter Hillman, who passed away while I was in the midst of writing the book. His influence has been felt throughout various stages of my career, particularly as they all coalesced in the following pages. My long-time friends and colleagues Dr. Denis Kay and Ken Cawkell provided many stimulating conversations related to topics in this book. My wife, Danika Surm, always found time in her incredibly busy schedule to allow me a few hours' work on this project here and there. My older children, Emma and Ariel, also helped in various ways, mostly serving as additional sounding boards for my endless babbling on the topics that follow. Joe's Café provided the caffeine that made it all feasible while I was writing in Vancouver.

Finally, I am most grateful to my department, Ophthalmology and Visual Sciences, and its various chairpersons over the years; to the Faculty of Medicine; and to the University of British Columbia itself. All have been supportive of my sometimes unconventional approaches to academic issues and all actually believe in that sometimes elusive application of the concept of academic freedom.

In this last year, as the book took shape in the various intellectual and geographically peripatetic ways in which it was written (Paris, Vancouver, Los Angeles, the Camino de Santiago, Lucy sur Yonne, and Victoria), my son Caius was born and my mother, Peggy O'Shea, and my father, Lou Shaw, died. This book is therefore dedicated to the future of my son and the memory of my parents. *Buen Camino* to my son as he travels through life and to my parents for lives well lived and long journeys well taken.

*Christopher A. Shaw
Victoria, BC, Canada*

Contents

Preface *xv*

Acknowledgments *xxi*

Part I The Dynamics of Neurological Disease *1*

- 1 The Dynamics of Neurological Disease: Current Views and Key Issues** *3*
 - 1.1 Introduction *4*
 - 1.2 The Complexity of Human Neurological Diseases *4*
 - 1.3 The Nervous System as an Archetypical Complex System *9*
 - 1.4 CNS Signaling Failures: Implications for Neurological Disease *14*
 - 1.5 History and Key Characteristics of the Age-Dependent Neurological Diseases *14*
 - 1.6 The Fractal Nature of Complexity in the CNS *16*
 - Endnotes *17*
- 2 Clinical and Economic Features of Age-Related Neurological Diseases** *19*
 - 2.1 Introduction *19*
 - 2.2 Parkinson's Disease *19*
 - 2.2.1 Neuropathological Features *20*
 - 2.2.2 The Parkinsonisms *23*
 - 2.2.3 Rating Schemes *23*
 - 2.2.3.1 Hoehn and Yahr Scale *23*
 - 2.2.3.2 Modified Hoehn and Yahr Scale *24*
 - 2.2.3.3 Schwab and England Activities of Daily Living Scale *24*
 - 2.2.3.4 Unified Parkinson's Disease Rating Scale *24*
 - 2.2.4 Progression *25*
 - 2.2.5 Other Organ System Involvement *25*
 - 2.2.6 Parkinson's Disease Clusters *25*
 - 2.2.7 Risk Factors *25*
 - 2.2.8 Current Treatment Options *26*
 - 2.2.9 Animal Models *26*
 - 2.2.10 Parkinson's Disease in Relation to Other Neurological Diseases *27*
 - 2.2.11 Demographics *27*

2.2.12	Incidence and Prevalence	27
2.2.12.1	United States and Canada	27
2.2.12.2	Worldwide	28
2.2.13	Changes in Incidence/Prevalence over the Last 30 Years	28
2.2.13.1	United States and Canada	28
2.2.14	Costs	28
2.2.14.1	Cost Per Patient	28
2.2.14.2	Societal Costs	28
2.2.14.3	Projected Cost Increases	29
2.3	Amyotrophic Lateral Sclerosis	29
2.3.1	Loci of Onset	29
2.3.2	Neuropathological Features	30
2.3.3	Rating Schemes	32
2.3.3.1	El Escorial Diagnostic Criteria	32
2.3.3.2	ALS Functional Rating Scale	32
2.3.3.3	Forced Vital Capacity	32
2.3.4	Progression	36
2.3.5	Rates of Disease Progression	36
2.3.6	Age of Onset and Sex Distribution	36
2.3.7	Other Organ System Involvement	36
2.3.8	ALS Clusters	36
2.3.9	Risk Factors	37
2.3.10	Current Treatment Options	37
2.3.11	ALS in Relation to Other Neurological Diseases and Disorders: Cognitive Impairment	37
2.3.12	ALS and Other CNS Regions	38
2.3.13	Animal Models	38
2.3.14	Incidence and Prevalence	38
2.3.14.1	United States and Canada	38
2.3.15	Changes in Incidence/Prevalence over the Last 30 Years	39
2.3.15.1	United States	39
2.3.15.2	Canada	39
2.3.15.3	Worldwide	39
2.3.16	Costs	39
2.3.16.1	Cost Per Patient	39
2.3.16.2	Societal Costs	40
2.4	Alzheimer's Disease	40
2.4.1	Neuropathological Features	41
2.4.2	Rating Schemes	42
2.4.2.1	Global Deterioration Scale	42
2.4.2.2	Functional Assessment Staging	43
2.4.2.3	Clinical Dementia Rating	43
2.4.3	Other Organ System Involvement	43
2.4.4	Alzheimer's Disease Clusters	44
2.4.5	Risk Factors	44
2.4.6	Current Treatment Options	44
2.4.7	Demographics	44
2.4.8	Incidence and Prevalence	45

2.4.8.1	United States	45
2.4.8.2	Canada	45
2.4.9	Changes in Incidence/Prevalence over the Last 30 Years	45
2.4.9.1	United States	45
2.4.10	Costs	45
2.4.10.1	Costs Per Patient	45
2.4.10.2	Societal Costs	46
2.4.10.3	Projected Cost Increases	46
2.5	Summary of the Data on the Progressive, Age-Related Neurological Diseases	47
2.6	Neural Loci and Mechanisms of Action	48
	Endnote	49
3	Spectrums of Neurological Disease, Clusters, and Ubiquity	51
3.1	Introduction	51
3.2	Spectrums of Neurological Disease	51
3.3	The Dimension of the Problem when Assessing Potential Causal Factors in Neurological Diseases	54
3.4	Neurological Disease Clusters	57
3.4.1	Lathyrism	58
3.4.2	Minimata	58
3.4.3	Domoic Acid	59
3.4.4	Summary	59
3.5	Ubiquity	60
3.6	Nested Complex Systems: Proximal versus Distal Events as They May Relate to Neurological Diseases	60
3.7	The Path to “Curing” Neurological Diseases	63
4	Complexity, Cascading Failures, and Neurological Diseases	67
4.1	Introduction	67
4.2	Introduction to Complexity Theory and Complex Systems	67
4.3	Computer Programs and Computer Crashes	69
4.4	Biosemosis in the CNS (Part 1)	70
4.4.1	Degraded Biological Signals in CNS Pathology	71
4.5	Complexity in the CNS and the Impact of Genetic and Environmental Insults	73
4.6	Tipping Points and Time Lines of Disease Progression	77
5	Genetic Determinants of Neurological Disease	79
5.1	Introduction	80
5.2	Causality versus Coincidence	80
5.3	Actions of Mutant Genes in Neurological Disease	82
5.3.1	Huntington’s Disease	83
5.4	Genetic Mutations Linked to Parkinson’s Disease	84
5.4.1	α -synuclein	85
5.4.2	<i>LRRK2</i>	85
5.4.3	Lesser Genes Associated with Autosomal-Recessive Forms of Parkinson’s Disease	86

5.4.4	Summary	86
5.5	Genetic Mutations Linked to ALS	86
5.5.1	<i>SOD1</i>	88
5.5.2	<i>TARDBP</i>	90
5.5.3	<i>FUS</i>	90
5.5.4	<i>UBQLN2</i>	91
5.5.5	<i>C9orf72</i>	91
5.5.6	Summary	92
5.6	Genetic Mutations Linked to Alzheimer's Disease	92
5.6.1	<i>APP</i>	92
5.6.2	Presenilin 1 (<i>PSEN1</i>)	94
5.6.3	Presenilin 2 (<i>PSEN2</i>)	94
5.7	Genes and Neurological Disease: Some General Considerations	94
6	Environmental Determinants of Neurological Disease and Gene-Toxin Interactions	97
6.1	Introduction	98
6.2	Toxins and Neurological Diseases	98
6.2.1	Pesticides, etc.	99
6.2.2	Toxic Metals	99
6.2.3	Amino Acids, Natural and Human-Made	100
6.2.4	Steryl Glucosides	100
6.2.5	Bisphenols	100
6.2.6	Summary	100
6.3	Aluminum and Neurological Disease	101
6.3.1	Some Background to Aluminum Chemistry and the Intersection of Aluminum with the Biosphere	102
6.4	Single- vs. Multiple-Hit Models of Neurological Disease: Gene-Toxin Interactions	114
6.5	Genetic Susceptibility Factors	117
6.5.1	Toxin-Triggering Genetic Alterations and Gene Expression Levels	118
6.5.2	miRNA Alterations in Gene Expression	122
6.6	Biosemiosis (Part 2)	123
6.6.1	Aluminum and Failed Biosemiosis	123
6.7	Gene-Toxin Interactions and Cascading Failures	124
6.8	Genes and Toxins in Neurological Disease: Penultimate Thoughts	124
6.9	And, Finally, the Microbiome	125
	Endnote	125
7	The Mystery and Lessons of ALS-PDC	127
7.1	Introduction	127
7.2	Neurological Disease Clusters and ALS-PDC	128
7.3	History and Features of ALS-PDC	129
7.4	Cycad and ALS-PDC	135
7.4.1	Human Consumption of Cycad	137
7.4.2	Cycad's Links to ALS-PDC	138
7.5	Amino Acid Toxins in Cycad and ALS-PDC	140
7.6	Non-Amino Acid Toxins Linked to ALS-PDC	143

- 7.7 Aluminum and Ionic Etiologies for ALS-PDC 147
- 7.8 Still Other Molecules Causal to ALS-PDC 148
- 7.9 What is the Current View on the Importance of ALS-PDC? 148
- 7.10 Complexity of Neurological Diseases as Viewed from Guam 151
- Endnote 151

Part II Age and Time Lines of Neurological Disease 153

- 8 Neurological Disease Models and their Discontents: Validity, Replicability, and the Decline Effect 155**
 - 8.1 Introduction 155
 - 8.2 Modeling Human Neurological Diseases: Possibilities and Pitfalls 156
 - 8.3 Considerations Regarding Model Systems 158
 - 8.4 Model Systems and their Discontents 159
 - 8.4.1 Age and Time in *In Vivo* Models as a Function of Species 164
 - 8.4.2 Replicability and the Problems Created by the Absence of the Same 165
 - 8.4.3 The “Decline Effect” 167
 - 8.5 Is There an Ideal Model for Studying Neurological Diseases? General Considerations 168
 - 8.6 Specific Considerations for Ideal Model-System Approaches in ALS 170
 - 8.6.1 ALS Considered from the Perspective of Model Systems: Lost in Translation 171
 - 8.7 Alternative Views of Neurological Disease and Model-Systems Approaches: Multiple-Hit Etiologies 172
- 9 The Progression and the Time Line of Neurological Disease 175**
 - 9.1 Introduction 175
 - 9.2 Creating Disease Time Lines: The Framingham Study 176
 - 9.3 Time Lines of Neurological Disease 176
 - 9.3.1 Braak Staging for Parkinson’s Disease 178
 - 9.3.2 Braak Staging for Alzheimer’s Disease 179
 - 9.3.3 Problems in Post-Clinical Staging 179
 - 9.3.4 Staging of Clinical Features and Pathology 180
 - 9.4 Back to a Multiple-Hit Disease Consideration 180
 - 9.5 Haecceity and Quiddity in Context to Biosemiosis and Multiple Hits 181
 - 9.6 Some Final Thoughts on Time Lines of Neurological Disease: Differentiation and Neurogenesis 182
 - Endnote 183
- 10 Development, Aging, and Neurological Disease 185**
 - 10.1 Introduction 185
 - 10.2 The Fetal Basis of Adult Disease Hypothesis 186
 - 10.3 ASD as a Developmental Neurological Disorder 188
 - 10.3.1 Etiology of ASD 189
 - 10.3.2 Juvenile Schizophrenia 192
 - 10.3.3 Juvenile-Onset Forms of ALS and Other Neurological Disorders 192
 - 10.4 Toxins and Developmental CNS Disorders 193

- 10.5 Developmental versus Mature CNS Disorders 193
- Endnotes 194

Part III Interactions and Synergies in Neurological Disease 195

- 11 CNS-Immune System Interactions and Autoimmunity 197**
 - 11.1 Introduction 198
 - 11.2 Immunity and the CNS, an Introduction to a Complex Topic 198
 - 11.2.1 Innate versus Adaptive Immune Systems and their Roles in CNS Development 198
 - 11.2.2 The Role of Microglia in Neurological Diseases 201
 - 11.3 CNS-Immune System Interactions: More Detailed Considerations 202
 - 11.3.1 Pathogen and Aluminum Activation of the Immune System in Relation to the CNS 203
 - 11.3.2 HPA-Immune System Interactions 203
 - 11.4 Autoimmunity 205
 - 11.4.1 Bidirectional Role of Immune System-CNS Interactions and Autoimmunity during Neuronal Development 206
 - 11.4.2 Autoimmunity and Neurological Diseases 207
 - 11.4.3 The Age-Related, Progressive Neurological Diseases and Autoimmunity 208
 - 11.5 Immune System Signaling Errors and Autoimmunity in ASD and Other Neurological Disorders 208
 - 11.5.1 Aluminum's Role in Immune-System Signaling Errors 209
 - 11.6 Laterality and Autoimmunity in Neurological Diseases 212
 - 11.7 Other System Disorders in Neurological Diseases: More Evidence for Autoimmunity? 215
 - 11.8 Are There Infectious Disease Links to Neurological Diseases? 215
- 12 The Impact of Synergy of Factors in Neurological Disease 219**
 - 12.1 Introduction 219
 - 12.2 Synergistic and Additive Effects in General and as Applied to CNS Diseases 219
 - 12.3 Gene-Environment (Toxin) Interactions in Non-neuronal Systems 221
 - 12.3.1 Genetic Polymorphism and Alcoholism 221
 - 12.3.2 Genetic Polymorphism and Lactose Intolerance 222
 - 12.3.3 Genetic Polymorphism and Gluten Intolerance 223
 - 12.4 Gene-Environment (Toxin) Interactions in Neurological Disease 224
 - 12.4.1 Summary of Gene-Toxin Interactions in Relation to Neurological Disease 225
 - 12.5 Levels of Complexity in Gene-Toxin Interactions: Implications for Current and Future Therapeutics 226

Part IV Transition and Politics in Neurological Disease 229

- 13 The Current Status of Neurological Disease Treatments 231**
 - 13.1 Introduction 231